Current Pharmaceutical Design , 2020 Injecting Far from the Injury Site (When Localized Healing Is Needed) If you're recovering from a joint, tendon, or ligament injury , injecting into the abdomen wont target the injured tissue as efficiently
maintenance phase is the heavy draw 26 weeks 13 vials Standard Phase 2 duration 32 weeks 16 vials Phase 2 T2D study duration 68 weeks 30 vials REDEFINE 1 / REDEFINE 2 endpoint duration Peptide Vials (10 mg vial, 2.4 mg/week target) Each 10 mg vial covers about 4 weekly doses at 2.4 mg/week
Benefits Tendon and ligament repair studied for accelerating recovery in connective tissues Muscle healing explored for regeneration after injury in preclinical models Gut protection linked to gastric and intestinal lining repair research Angiogenesis promotes new blood vessel formation in healing tissues Cell signaling associated with fibroblast migration, collagen production, and nitric oxide modulation Localized Effects with Nasal Spray Rapid uptake through the nasal mucosa Direct access to systemic and central healing pathways in preclinical models Formulated with a specialized isotonic nasal vehicle to minimize irritation and dryness What Researchers Use It For Angiogenesis and vascularization in soft tissue recovery Fibroblast migration and collagen deposition pathways Protection of gastric and intestinal lining in animal studies Neuroprotective and anti-inflammatory signals in preclinical research Identity & Specs Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val Formula / M.W.: C62H98N16O22, ~1419 g/mol CAS: 137525-51-0 Form: Sterile nasal spray solution Net per vial: 10 mL (~100 sprays) Total Content: 10 mg BPC-157 per vial Purity: 99% (HPLC) Identity: MS-verified (per COA) Storage: Refrigerate 28 C, protect from light Selected Research PubChem entry chemical identity: Tendon and ligament healing research: Gut protection and gastric healing studies: Angiogenesis and tissue repair (animal models): Nitric oxide and healing pathways: Disclaimer This product is intended for laboratory research use only
However, it is not FDA-approved for medical treatment or injection, and regulatory status may vary by use
TB500 for 4 to 8 weeks
BPC-157 first appeared in the early 1990s, when European researchers wondered why some stomach ulcers healed quickly while others didnt, Flynn McGuire, a physical medicine and rehabilitation resident at the University of Utah who is about to enter a sports medicine fellowship, tells Outside Run
